Mitoxantron Ebewe (Mitoxantrone)

Mitoxantrone intercalates into DNA and blocks topoisomerase II activity, leading to DNA strand breaks that trigger apoptosis of rapidly dividing malignant cells, thereby reducing tumor burden.

The dose of Mitoxantron Ebewe is individualized by the treating physician based on the specific indication, patient weight, renal function, and treatment protocol. Only a qualified prescriber may determine the appropriate regimen.

Mitoxantron Ebewe is classified as Pregnancy Category D, indicating evidence of fetal risk. It should not be used during pregnancy, and breastfeeding is contraindicated because the drug can be excreted in milk.

To request Mitoxantron Ebewe, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with other anthracenediones, mitoxantrone offers a broader spectrum covering both hematologic malignancies and certain solid tumours. Its cardiotoxicity profile is similar to anthracyclines, so cardiac monitoring is essential, while its efficacy in progressive multiple sclerosis is a unique therapeutic advantage.

Mitoxantron Ebewe must be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. Keep the vial in its original packaging until use to maintain stability.

The product is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional under aseptic conditions, typically over a prescribed period of time based on the treatment protocol.

Serious risks include cardiotoxicity, secondary acute leukemia, severe infections due to profound myelosuppression, and hepatic toxicity. Patients should be closely monitored for cardiac function, blood counts, and liver enzymes throughout therapy.

Mitoxantron Ebewe is contraindicated in patients with known hypersensitivity to mitoxantrone, those with uncontrolled cardiac disease, pregnant or breastfeeding women, and individuals with severe hepatic impairment unless benefits outweigh risks.